Gelman L, Fruchart J C, Auwerx J
INSERM U 325, Département d'Athérosclérose, Institut Pasteur, Lille, France.
Cell Mol Life Sci. 1999 Jun;55(6-7):932-43. doi: 10.1007/s000180050345.
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors and have been initially described as molecular targets for compounds which induce peroxisome proliferation. The interest of researchers for PPARs increased dramatically when these receptors were shown to be directly activated by a number of medically relevant compounds. These compounds include: the fibrate class of hypolidemic drugs, the thiazolidinediones, which are insulin sensitizers used as orally active antidiabetic agents, certain non-steroidal anti-inflammatory drugs (NSAIDs), and naturally occurring fatty acid-derived molecules. Rapidly, it was demonstrated that PPARs are key regulators of lipid homeostasis and provide a molecular link between nutrition and gene regulation. Recently, detailed studies of PPAR expression profiles in different tissues pointed to the roles these receptors play in inflammation control and cell proliferation. In this review we will focus on the new insights gained into these two areas and we will also discuss our current knowledge of the regulation of PPAR transcriptional activity by cofactors.
过氧化物酶体增殖物激活受体(PPARs)是核受体,最初被描述为诱导过氧化物酶体增殖的化合物的分子靶点。当这些受体被多种医学相关化合物直接激活时,研究人员对PPARs的兴趣急剧增加。这些化合物包括:降血脂药物中的贝特类、用作口服活性抗糖尿病药物的胰岛素增敏剂噻唑烷二酮类、某些非甾体抗炎药(NSAIDs)以及天然存在的脂肪酸衍生分子。很快,人们就证明PPARs是脂质稳态的关键调节因子,并在营养与基因调控之间提供了分子联系。最近,对不同组织中PPAR表达谱的详细研究揭示了这些受体在炎症控制和细胞增殖中所起的作用。在这篇综述中,我们将重点关注在这两个领域获得的新见解,同时也将讨论我们目前对辅因子调节PPAR转录活性的认识。